These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 33356652)

  • 1. Combined ablation-chemotherapy versus chemotherapy alone for pancreatic cancer with liver metastasis: a propensity score matching study.
    Yan X; Ning ZY; Wang P; Zhuang LP; Xu LT; Zhu ZF; Sheng J; Shen YH; Hua YQ; Meng ZQ
    Expert Rev Gastroenterol Hepatol; 2021 Sep; 15(9):1047-1056. PubMed ID: 33356652
    [No Abstract]   [Full Text] [Related]  

  • 2. Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial.
    Motoi F; Ishida K; Fujishima F; Ottomo S; Oikawa M; Okada T; Shimamura H; Takemura S; Ono F; Akada M; Nakagawa K; Katayose Y; Egawa S; Unno M
    Ann Surg Oncol; 2013 Nov; 20(12):3794-801. PubMed ID: 23838925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The investigation of the survival time after recurrence in patients with pancreatic ductal adenocarcinoma for individualization of adjuvant chemotherapy.
    Yamada D; Eguchi H; Iwagami Y; Asaoka T; Noda T; Kawamoto K; Gotoh K; Kobayashi S; Mori M; Doki Y
    Surg Today; 2018 Oct; 48(10):952-962. PubMed ID: 29770847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
    Oba A; Ban D; Kirimura S; Akahoshi K; Mitsunori Y; Matsumura S; Ochiai T; Kudo A; Tanaka S; Minoru T
    J Hepatobiliary Pancreat Sci; 2016 Aug; 23(8):480-8. PubMed ID: 27247050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined analysis of dihydropyrimidine dehydrogenase and human equilibrative nucleoside transporter 1 expression predicts survival of pancreatic carcinoma patients treated with adjuvant gemcitabine plus S-1 chemotherapy after surgical resection.
    Kondo N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakashima A; Sueda T
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S646-55. PubMed ID: 22086444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unresectable pancreatic ductal adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy.
    Cheng SH; Cheng YJ; Jin ZY; Xue HD
    Eur J Radiol; 2019 Apr; 113():188-197. PubMed ID: 30927946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful management of metachronous liver metastasis after pancreaticoduodectomy for pancreatic ductal carcinoma using hepatectomy and chemotherapy: a case report.
    Iida T; Nakabayashi Y; Okui N; Shiba H; Otsuka M; Yanaga K
    Anticancer Res; 2014 May; 34(5):2417-20. PubMed ID: 24778053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The high stromal SPARC expression is independently associated with poor survival of patients with resected pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine in combination with S-1 or adjuvant gemcitabine alone.
    Shintakuya R; Kondo N; Murakami Y; Uemura K; Nakagawa N; Okano K; Takahashi S; Sueda T
    Pancreatology; 2018 Mar; 18(2):191-197. PubMed ID: 29295776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of intrahepatic and pancreatic perfusion on fusion images using a combined SPECT/CT system and assessment of efficacy of combined continuous arterial infusion and systemic chemotherapy in advanced pancreatic carcinoma.
    Ikeda O; Tamura Y; Nakasone Y; Shiraishi S; Kawanaka K; Tomiguchi S; Yamashita Y; Takamori H; Kanemitsu K; Baba H
    Cardiovasc Intervent Radiol; 2007; 30(5):912-21. PubMed ID: 17710478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma.
    Tomihara H; Eguchi H; Yamada D; Gotoh K; Kawamoto K; Wada H; Asaoka T; Noda T; Takeda Y; Tanemura M; Mori M; Doki Y
    Surg Today; 2017 Feb; 47(2):218-226. PubMed ID: 27586014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival of patients with non-resectable, chemotherapy-resistant colorectal cancer liver metastases undergoing conventional lipiodol-based transarterial chemoembolization (cTACE) palliatively versus neoadjuvantly prior to percutaneous thermal ablation.
    Vogl TJ; Lahrsow M; Albrecht MH; Hammerstingl R; Thompson ZM; Gruber-Rouh T
    Eur J Radiol; 2018 May; 102():138-145. PubMed ID: 29685527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative analysis of vascular endothelial growth factor in liver metastases from pancreatic carcinoma as a predictor of chemotherapeutic effect and prognosis.
    Tawada K; Ishihara T; Kobayashi A; Yamaguchi T; Tsuyuguchi T; Matsuyama M; Yokosuka O
    Clin Cancer Res; 2008 Nov; 14(22):7438-43. PubMed ID: 18974391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort study.
    Imaoka H; Ikeda M; Maehara K; Umemoto K; Ozaka M; Kobayashi S; Terashima T; Inoue H; Sakaguchi C; Tsuji K; Shioji K; Okamura K; Kawamoto Y; Suzuki R; Shirakawa H; Nagano H; Ueno M; Morizane C; Furuse J
    BMC Cancer; 2020 Oct; 20(1):946. PubMed ID: 33004032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma.
    Vienot A; Beinse G; Louvet C; de Mestier L; Meurisse A; Fein F; Heyd B; Cleau D; d'Engremont C; Dupont-Gossart AC; Lakkis Z; Tournigand C; Bouché O; Rousseau B; Neuzillet C; Bonnetain F; Borg C; Vernerey D
    J Natl Cancer Inst; 2017 Oct; 109(10):. PubMed ID: 28383673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic arterial infusion chemotherapy reduced hepatic metastases from pancreatic cancer after pancreatectomy.
    Zheng YY; Tang CW; Xu YQ; Feng WM; Bao Y; Fei MY
    Hepatogastroenterology; 2014; 61(133):1415-20. PubMed ID: 25436319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined Therapy of Chemotherapy and Radiofrequency Ablation for Pancreatic Cancer Patients With Metachronous Hepatic Metastatic Lesions After Radical Pancreatic Resection.
    Wang LT; Yang J; Wu J; Lu WJ
    Cancer Control; 2024; 31():10732748241274559. PubMed ID: 39150275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the significance of adjuvant chemotherapy in patients with stage ⅠA pancreatic ductal adenocarcinoma.
    Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Matsunaga Y; Shiihara M; Yamamoto M
    Pancreatology; 2021 Apr; 21(3):581-588. PubMed ID: 33579600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S-1 vs. gemcitabine as an adjuvant therapy after surgical resection for ductal adenocarcinoma of the pancreas.
    Okabayashi T; Shima Y; Iwata J; Morita S; Sumiyoshi T; Kozuki A; Tokumaru T; Iiyama T; Kosaki T; Kobayashi M; Hanazaki K
    World J Surg; 2014 Nov; 38(11):2986-93. PubMed ID: 25104544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiofrequency ablation of liver metastasis in patients with locally controlled pancreatic ductal adenocarcinoma.
    Park JB; Kim YH; Kim J; Chang HM; Kim TW; Kim SC; Kim PN; Han DJ
    J Vasc Interv Radiol; 2012 May; 23(5):635-41. PubMed ID: 22525021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized phase II trial of adjuvant chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer.
    Yoshitomi H; Togawa A; Kimura F; Ito H; Shimizu H; Yoshidome H; Otsuka M; Kato A; Nozawa S; Furukawa K; Miyazaki M;
    Cancer; 2008 Nov; 113(9):2448-56. PubMed ID: 18823024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.